Patient satisfaction with information on oral anticancer agent use.
Patient satisfaction with information on oral anticancer agent use.
复制标题
患者对使用口服抗癌剂的信息的满意度。
DOI：
10.1002/cam4.1239
复制
发表时间：
2018-01
期刊：
影响因子：
4
通讯作者：
Hugtenburg JG
中科院分区：
文献类型：
--
作者：
Boons CCLM;Timmers L;van Schoor NM;Swart EL;Hendrikse NH;Janssen JJWM;Hugtenburg JG
有关口服抗癌剂 (OACA) 使用的充分信息是最佳癌症护理的重要组成部分。本研究旨在深入了解患者对 OACA 治疗信息的体验以及他们对信息不满意的特征。使用 OACA 的四家荷兰大学医院的患者参与了这项观察性研究，并完成了药物信息满意度量表 (SIMS)、EORTC 生活质量问卷 -C30、简要疾病感知问卷和药物信念问卷 - 具体。使用逻辑回归分析来确定与信息不满意相关的因素。使用卡培他滨 (35%)、来那度胺 (15%)、伊马替尼 (14%)、替莫唑胺 (12%)、舒尼替尼 (11%)、沙利度胺 (5%)、达沙替尼 (4%)、厄洛替尼 (2%) 和尼洛替尼 (2%) 的患者 (n = 208) 参与。以下 SIMS 项目的信息不充分：OACA 如何产生作用、治疗需要多长时间才能起效、如何得出治疗有效的结论、副作用的风险及其管理、对性生活的干扰、嗜睡、对其他药物和酒精的干扰以及错过剂量时该怎么办。年龄较小、血液恶性肿瘤、呼吸困难、对癌症后果的积极认知、对治疗控制的低认知以及对 OACA 的冷漠态度与对信息的不满有关。总之，相当多的患者希望获得有关 OACA 治疗后果的具体问题的更多信息，例如 OACA 的作用和副作用以及治疗对日常生活各个方面的干扰。肿瘤学家、血液学家、肺肿瘤学家和药剂师可能会重新考虑提供有关 OACA 治疗的信息。
Adequate information on oral anticancer agent (OACA) use is an essential element of optimal cancer care. The present study aimed to get insight into the experiences of patients with information on OACA treatment and their characteristics regarding information dissatisfaction. Patients of four Dutch university hospitals using OACA participated in this observational study and completed the Satisfaction with Information about Medicines Scale (SIMS), EORTC Quality of Life Questionnaire‐C30, Brief Illness Perception Questionnaire, and Beliefs about Medicines Questionnaire‐Specific. Logistic regression analyses were used to determine factors associated with dissatisfaction with information. Patients (n = 208) using capecitabine (35%), lenalidomide (15%), imatinib (14%), temozolomide (12%), sunitinib (11%), thalidomide (5%), dasatinib (4%), erlotinib (2%), and nilotinib (2%) participated. Information on the following SIMS‐items was inadequate: how OACA elicit their effect, how long it takes before treatment works, how to conclude that treatment is effective, the risk of side effects and its management, interference with sex life, drowsiness, interference with other medication and alcohol and what to do in case of a missed dose. Younger age, hematological malignancy, dyspnoea, positive perception of consequences of the cancer, low perception of treatment control, and indifferent attitude towards OACA were associated with dissatisfaction with information. In conclusion, a considerable number of patients would have appreciated receiving more information on specific issues relating to the consequences of OACA treatment such as the effects and side effects of OACA and the interference of treatment with various aspects of their daily life. Oncologists, hematologists, lung‐oncologists and pharmacists may reconsider the provision of information on OACA treatment.
登录
查看更多内容
DOI：
10.1186/2049-3258-72-37
发表时间：
2014
期刊：
Archives of public health = Archives belges de sante publique
影响因子：
--
作者：
Mathes T;Jaschinski T;Pieper D
通讯作者：
Pieper D
影响因子：
3.6
作者：
Husson, Olga;Thong, Melissa S. Y.;van de Poll-Franse, Lonneke V.
通讯作者：
van de Poll-Franse, Lonneke V.
DOI：
10.1177/1078155211436022
发表时间：
2012-09-01
期刊：
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
影响因子：
--
作者：
Bhattacharya, Debi;Easthall, Claire;Watson, Steven
通讯作者：
Watson, Steven
影响因子：
3.7
作者：
Faller, Hermann;Koch, Uwe;Mehnert, Anja
通讯作者：
Mehnert, Anja
影响因子：
3.8
作者：
Timmers, Lonneke;Boons, Christel C. L. M.;Hugtenburg, Jacqueline G.
通讯作者：
Hugtenburg, Jacqueline G.